Markets:

Overview

News

Currencies

International

Treasuries

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

11.63 -0.38 (-3.16%)

Streaming Delayed Price Updated: 9:58 AM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

The Law Offices of Frank R. Cruz Announces Investigation of Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors

March 01, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗

February 28, 2023

Via Benzinga

uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

February 28, 2023

UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market...

Via Benzinga

What 6 Analyst Ratings Have To Say About Fulcrum Therapeutics ↗

February 27, 2023

Via Benzinga

Expert Ratings for Fulcrum Therapeutics ↗

January 19, 2023

Via Benzinga

Why Fulcrum Therapeutics Shares Are Falling ↗

January 18, 2023

Fulcrum Therapeutics Inc (NASDAQ: FULC) shares are trading lower by 6.43% to $13.09 Wednesday morning after the company announced pricing of an upsized public offering of common stock.

Via Benzinga

Dow Dips 350 Points; S&P 500 Down Over 1% ↗

February 24, 2023

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday. The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500...

Via Benzinga

Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 24, 2023

Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.

Via Benzinga

Stocks Extend Slump, Head For Weekly Losses ↗

February 24, 2023

Stocks are extending their premarket losses, with the Dow Jones Industrial Average down 409 points.

Via Talk Markets

Looking Into Fulcrum Therapeutics's Return On Capital Employed ↗

December 06, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 24, 2023

Via Benzinga

Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher ↗

February 24, 2023

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also...

Via Benzinga

FDA Slams Break On Fulcrum Therapeutics' Sickle Cell Disease Study, Shares Plummet ↗

February 24, 2023

Via Benzinga

Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News ↗

February 24, 2023

FULC stock is falling fast today due to a regulatory issue, but Fulcrum Therapeutics remains committed to combating sickle cell disease.

Via InvestorPlace

US Stocks Open Lower; Dow Drops 1% ↗

February 24, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 24, 2023

Via Benzinga

Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

February 24, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference

February 08, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying ↗

January 25, 2023

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

Via Benzinga

The Week In Charts - Becoming A Successful Trader ↗

January 21, 2023

Dave discusses various topics, including intra-day trading and trading opening gap reversals, the current stock market conditions, and his two cents on your favorite stock picks.

Via Talk Markets

Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

January 17, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 17, 2023

Via Benzinga

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

January 17, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 16, 2023

Via Benzinga

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 13, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

$3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying ↗

January 09, 2023

Although US stocks closed sharply higher on Friday, there were a few notable insider trades.

Via Benzinga

Fulcrum Therapeutics Provides Business Update and 2023 Outlook

January 04, 2023

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics Announces CEO Transition

January 04, 2023

Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum, is appointed as interim CEO as Bryan Stuart departs to pursue other opportunities

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying ↗

December 19, 2022

Although US stocks closed lower on Friday, there were a few notable insider trades.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.